high drug prices inflate ceos’ paypharmaceutical companies say profits fund research innovation new medicines spending billions enrich shareholders executivesmr lazonick emeritus professor economics university massachusetts lowell mr tulum postdoctoral fellow soas university londondrug company executives faced tough questions congress tuesday attempted explain why thanks high drug prices per capita spending pharmaceuticals united states double average advanced countries decades american drug makers justified high prices asserting higher profits generate fund research accelerates development new medicines data shows however companies spend every penny profits distributions shareholders forms cash dividends stock buybacksbecause greater part management compensation linked stock price prime beneficiaries abuse corporate profits executives claim high drug prices redound common good time drug giants merck pfizer seem become focused buying companies successful new drugs rather developing owncongress raising alarms drug prices years  representative henry waxman california democrat chairman house health subcommittee accused pharmaceutical industry “gouging american public” driven “greed massive scale” escalation drug prices gotten worse documented various senate investigationsdespite claims big american drug companies using profits high prices ramp investment drug development research shows  pharmaceutical companies s  p distributed percent combined profits shareholders  billion buybacks  billion dividends distributions percent greater companies spent research developmentwith compensation coming exercising stock options stock awards senior executives benefit immensely gathered data highestpaid executives united states  number came drug industry ranged in  in  total compensation executives averaged  million compared average already overthetop  million a total percent compensation based stock  drug executives top averaged  million total compensation percent stockbased jacking product prices distributing increased profits shareholders executives lift stock prices takehome payour research institute new economic thinking demonstrates companies even show substantial r  d spending books much show it example merck distributed percent profits shareholders  pfizer percent although companies recorded large sums spent r  d — merck  billion pfizer  billion decade — companies generated revenues acquiring companies patented drugs market rather developing new drugs since  analysis pfizer significant revenues four internally originated developed products since merck’s merger scheringplough  two blockbuster drugs one result research public foots bill behavior pay high drug prices tax dollars supply  billion per year lifesciences research national institutes health yet like american companies drug industry claims corporations need pay lower corporate taxes remain competitive globally european pharmaceutical companies roche astrazeneca hand used american drug ecosystem — profits high drug prices scientific advances resulting government research funding — become leaders medical innovation roche dominates market specialty drugs oncology immunotherapy astrazeneca strong pipeline latest phases development merck pfizer comparison fallen seriously behindcongress put end madness government funds medical research grants patents intellectual property protections make pharmaceutical industry’s products financially viable therefore regulate drug prices united states also redesign executive pay reward drug company leaders actually bring new innovations market ban forms stock buybacks nothing manipulation stock market makes rich even richer reinvesting hundreds billions dollars american drug companies squandering buybacks would big step path affordable health care allwilliam lazonick emeritus professor economics university massachusetts lowell president academicindustry research network öner tulum postdoctoral fellow soas university london senior researcher times committed publishing diversity letters editor we’d like hear think articles tips here’s email lettersnytimescomfollow new york times opinion section facebook twitter nytopinion instagram